Tuesday, June 17, 2025 11:03:31 PM
How long have you owned NWBO? I ask because you have learned nothing in that time. You posted about phase 1 trials (one was even pre-phase 1, how AI will help find personal treatments). It takes a ton of money and years to get from ph 1 to ph 2/3 TLD and then submission to an RA and another year or longer after that. The articles you posted are about pure research. Not relevant to the current situation with NWBO. What part of that don't you understand yet?
The wait on MHRA is indeed frustrating. Once NWBO gets that approval, they still need to execute the commercial rollout. Expect to hear more about dc-vax once it's approved but the main audience will be the very limited number of neurology clinicians in the UK, not the general public. If and when dc-vax-l gets approved, it will be ginormous. Dc-vax-direct might be huge and might get through clinical testing and approval a lot faster, but at this point, the whole enchilada is on DcVax-l finally getting approved, and that's on the MHRA. If you don't understand all that already, sorry to have to say it, but you should never have invested in any individual biotech stock. Whining generally doesn't make anything in life happen more quickly.
The wait on MHRA is indeed frustrating. Once NWBO gets that approval, they still need to execute the commercial rollout. Expect to hear more about dc-vax once it's approved but the main audience will be the very limited number of neurology clinicians in the UK, not the general public. If and when dc-vax-l gets approved, it will be ginormous. Dc-vax-direct might be huge and might get through clinical testing and approval a lot faster, but at this point, the whole enchilada is on DcVax-l finally getting approved, and that's on the MHRA. If you don't understand all that already, sorry to have to say it, but you should never have invested in any individual biotech stock. Whining generally doesn't make anything in life happen more quickly.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
